- $194.29m
- -$2.45m
- $21.05m
Brief: Alector Provides Executive Leadership Update
Alector Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Alector Q1 Basic EPS USD -0.41
Alector Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Alector Announces Completion Of Enrollment In The Progress-Ad Phase 2 Clinical Trial Of Al101/Gsk4527226 In Individuals With Early Alzheimer’S Disease
Alector Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Alector Q4 Basic EPS USD -0.02
Alector Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Alector Reports On Recent Progress And Outlines Strategic Priorities For 2025
Brief: Abbvie Provided Written Notice To Alector, Terminating Trem2 Program
U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart
U.S. STOCKS ON THE MOVE-Goldman Sachs, Zoom, Rumble
U.S. STOCKS ON THE MOVE-Pinterest, Best Buy, Chevron
U.S. STOCKS ON THE MOVE-Rivian, Wells Fargo, Woodward
U.S. STOCKS ON THE MOVE-Everest, Zoom, Semtech
Alector tumbles as Alzheimer's drug fails trial
U.S. RESEARCH ROUNDUP-Allstate, Mongodb, Primerica
Brief: Alector Initiated A Reduction In Force Impacting About 41 Employees Across Organization
Brief: Alector Announces Results From Phase 2 Trial In Individuals With Early Alzheimer’s Disease